Glucotrol XL Side Effects
Generic Name: Glipizide
Please note - some side effects for Glucotrol XL may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
|
For the consumer For the professional
|
Side Effects of Glucotrol XL - for the consumer
Glucotrol XL Extended-Release Tablets
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Glucotrol XL Extended-Release Tablets:
Seek medical attention right away if any of these SEVERE side effects occur when using Glucotrol XL Extended-Release Tablets:Diarrhea; dizziness; gas; nausea.
TopSevere allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; skin redness; dizziness); confusion; dark urine; fainting; fever, chills, or persistent sore throat; irregular heartbeat; low blood sugar symptoms (eg, anxiety, drowsiness, fast heartbeat, headache, lightheadedness, severe or persistent dizziness, tremors, unusual sweating, weakness); severe or persistent blurred vision or other vision problems; unusual bruising or bleeding; unusual tiredness or weakness; yellowing of the eyes or skin.
For the professional
Glucotrol XL
In U.S. controlled studies the frequency of serious adverse experiences reported was very low and causal relationship has not been established.
The 580 patients from 31 to 87 years of age who received Glucotrol XL Extended Release Tablets in doses from 5 mg to 60 mg in both controlled and open trials were included in the evaluation of adverse experiences. All adverse experiences reported were tabulated independently of their possible causal relation to medication.
Hypoglycemia
See PRECAUTIONS and OVERDOSAGE sections.
Only 3.4% of patients receiving Glucotrol XL Extended Release Tablets had hypoglycemia documented by a blood-glucose measurement <60 mg/dL and/or symptoms believed to be associated with hypoglycemia. In a comparative efficacy study of Glucotrol XL and Glucotrol, hypoglycemia occurred rarely with an incidence of less than 1% with both drugs.
In double-blind, placebo-controlled studies the adverse experiences reported with an incidence of 3% or more in Glucotrol XL-treated patients include:
| Glucotrol XL (%) | Placebo (%) | |
|---|---|---|
| (N=278) | (N=69) | |
| Adverse Effect | ||
| Asthenia | 10.1 | 13.0 |
| Headache | 8.6 | 8.7 |
| Dizziness | 6.8 | 5.8 |
| Nervousness | 3.6 | 2.9 |
| Tremor | 3.6 | 0.0 |
| Diarrhea | 5.4 | 0.0 |
| Flatulence | 3.2 | 1.4 |
The following adverse experiences occurred with an incidence of less than 3% in Glucotrol XL-treated patients:
- Body as a whole–pain
- Nervous system–insomnia, paresthesia, anxiety, depression and hypesthesia
- Gastrointestinal–nausea, dyspepsia, constipation and vomiting
- Metabolic–hypoglycemia
- Musculoskeletal–arthralgia, leg cramps and myalgia
- Cardiovascular–syncope
- Skin–sweating and pruritus
- Respiratory–rhinitis
- Special senses–blurred vision
- Urogenital–polyuria
Other adverse experiences occurred with an incidence of less than 1% in Glucotrol XL-treated patients:
- Body as a whole–chills
- Nervous system–hypertonia, confusion, vertigo, somnolence, gait abnormality and decreased libido
- Gastrointestinal–anorexia and trace blood in stool
- Metabolic–thirst and edema
- Cardiovascular–arrhythmia, migraine, flushing and hypertension
- Skin–rash and urticaria
- Respiratory–pharyngitis and dyspnea
- Special senses–pain in the eye, conjunctivitis and retinal hemorrhage
- Urogenital–dysuria
Although these adverse experiences occurred in patients treated with Glucotrol XL, a causal relationship to the medication has not been established in all cases.
There have been rare reports of gastrointestinal irritation and gastrointestinal bleeding with use of another drug in this non-deformable sustained release formulation, although causal relationship to the drug is uncertain.
In post-marketing experience of Glucotrol XL, the additional adverse reaction of abdominal pain has been reported.
The following are adverse experiences reported with immediate release glipizide and other sulfonylureas, but have not been observed with Glucotrol XL:
Hematologic
Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.
Metabolic
Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas. In the mouse, glipizide pretreatment did not cause an accumulation of acetaldehyde after ethanol administration. Clinical experience to date has shown that glipizide has an extremely low incidence of disulfiram-like alcohol reactions.
Endocrine Reactions
Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with glipizide and other sulfonylureas.
Laboratory Tests
The pattern of laboratory test abnormalities observed with glipizide was similar to that for other sulfonylureas. Occasional mild to moderate elevations of SGOT, LDH, alkaline phosphatase, BUN and creatinine were noted. One case of jaundice was reported. The relationship of these abnormalities to glipizide is uncertain, and they have rarely been associated with clinical symptoms.
TopMore resources:
Glucotrol XL Extended-Release Tablets
Glucotrol XL - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.




